Summary
The metabolic fate of furosemide was studied in kidney transplant patients after oral and intravenous administration of the diuretic at therapeutic doses. Serial urine samples were collected over a 24 h period and furosemide was analyzed by a specific high performance liquid chromatographic method using fluorescence detection. We found no evidence of the putative furosemide metabolite, 2-amino-4-chloro-5-sulfamoylanthranilic acid (CSA), in any of the samples analyzed. The amount of furosemide excreted as the glucuronide metabolite accounted for 8% of the available dose, whether administered orally or by intravenous infusion. In addition, the significant positive correlation observed between the percent of the available dose excreted as furosemide glucuronide and the renal clearance of furosemide (r=0.581,p<0.02) suggests that the glucuronidation process for furosemide may be occurring in the kidney. Furosemide and its glucuronide metabolite accounted for only 45% of the intravenous dose recovered in the urine. Biliary excretion of unchanged furosemide and/or furosemide glucuronide into the feces probably accounts for the remainder of the dose not recovered.
Similar content being viewed by others
References
Benet LZ (1979) Pharmacokinetics/pharmacodynamics of furosemide in man: A review. J Pharmacokinet Biopharm 7: 1–27
Cutler RE, Blair AD (1979) Clinical pharmacokinetics of furosemide. Clin Pharmacokinet 4: 279–296
Smith DE, Lin ET, Benet LZ (1980) Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite specific assay. Drug Metab Dispos 8: 337–342
Smith DE, Gambertoglio JG, Vincenti F, Benet LZ (1981) Furosemide kinetics and dynamics after kidney transplant. Clin Pharmacol Ther 30: 105–113
Verbeeck RK, Gerkens JF, Wilkinson GR, Branch RA (1981) Disposition of furosemide in functionally hepatectomized dogs. J Pharmacol Exp Ther 216: 479–483
Andreasen F, Pedersen OL, Mikkelsen E (1978) Distribution, elimination and natriuretic effect of furosemide in patients with severe arterial hypertension. Eur J Clin Pharmacol 4: 237–244
Andreasen F, Christensen CK, Jakobsen FK, Morgensen CE (1981) The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products. Acta Pharmacol Toxicol 49: 223–229
Beermann B, Dalén E, Lindström B (1977) Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 22: 70–78
Rupp W (1974) Pharmacokinetics and pharmacodynamics of lasix. Scot Med J 19: 5–13
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, D.E., Benet, L.Z. Biotransformation of furosemide in kidney transplant patients. Eur J Clin Pharmacol 24, 787–790 (1983). https://doi.org/10.1007/BF00607088
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607088